The life sciences industry is experiencing a surge of scientific and technology advances. However, there remains a size-able gap between the innovations and the technologies in order to translate them into useful therapies. The U.S. Food and Drug Administration (FDA) is endeavoring to close that gap with an initiative to foster modernization in the life sciences industry - beginning with its own technology infrastructure.

In 2019, the agency introduced its Technology Modernization Action Plan (TMAP), a program designed to bring the organization up to speed with the latest technologies in order to expedite breakthrough discoveries with the intent of improving public health.

This publication provides an in-depth look at the FDA’s transformation and addresses how the agency’s initiative will impact manufacturers of regulated products.